Loading…
← CockpitCompetitor Analysis › 300298.SZ Sinocare Inc. Class AOpen in the cockpit ↗

Sinocare Inc. Class A300298.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.

≈ China's LifeScan/Ascensia for glucose metersMomentum leader 94
Mkt cap
$1.45B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$40.1M
20-day average traded
Fwd P/E
21.5×
forward earnings
ROIC−WACC
+2.2 pp
WACC 6.1%
Hurdle
-9 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥17.51
1D-1.6%
1W-5.2%
1M+5.6%
3M+5.8%
6M+4.0%
YTD+2.3%
1Y-5.9%
ATR %3.4%
52w lowhigh13.8% off high

What Sinocare does

China's leading maker of blood-glucose meters and diabetes home-monitoring devices for consumers.

Sells meters cheaply and earns on the test strips patients buy again and again, so every installed meter feeds repeat revenue. Most sales are in China through pharmacies and distributors, with exports a smaller part. It has added its own continuous glucose monitor, which reads sugar through a sensor worn on the skin.

In one line: China's LifeScan/Ascensia for glucose meters.

Products and services

  • Blood glucose meters
  • Test strips
  • Continuous glucose monitors

Customers

  • Retail pharmacies
  • Diabetic consumers
  • Export distributors

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Home diabetes monitoring devices

What could go right

  • China diabetes prevalence growth
  • CGM category expansion

What could go wrong

  • Glucose-meter price competition
  • CGM entry investment costs

Moat: narrow (brand, distribution, installed base). Leading domestic brand with wide pharmacy distribution and installed meter base.

Headquarters: Changsha, Hunan, China · Founded: 2002 · Employees: 5,010

Named competitors

  • Andon Health 002432.SZ
  • Roche Diabetes Care private or unlisted
  • Ascensia Diabetes Care private or unlisted

Sinocare at a glance

Size Sinocare (300298.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.45B, the 1559th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.51 on 18 Nov 2026.

Performance Over six months the shares gained 4.0%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 7.3% over the last twelve months (peer median +12.1%); the operating margin is 5.7% (peer median 8.2%).

Valuation It trades at 21.5× forward earnings against a peer median of 27.0× (7th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.2 points above its cost of capital (6.1% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026300298.SZ 105Peer median 92
Six months, rebased to 100: Sinocare against the median of its 20 peers (local-currency closes).

Sinocare financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.05BCN¥4.64BCN¥4.42BCN¥4.04BCN¥3.93B
Revenue growth—+5%+9%+3%—
Gross profitCN¥2.70BCN¥2.14BCN¥2.29BCN¥2.03BCN¥1.96B
EBITDAn/aCN¥396MCN¥610MCN¥548MCN¥565M
Net incomeCN¥253MCN¥92.6MCN¥326MCN¥284MCN¥447M
Free cash flowCN¥392MCN¥408MCN¥446MCN¥390MCN¥366M
Capital expenditureCN¥147MCN¥199MCN¥187MCN¥347MCN¥320M
Total debtCN¥1.09BCN¥960MCN¥959MCN¥1.22BCN¥1.60B

Quarterly statements and history in the cockpit →

Sinocare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%300049PRCTELNCNMD6880166849ENOVVITR6885313005953010876881986887583006336699BFLYSTAA8086NVCRINSP300298.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Sinocare is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×300049ELNCNMD6880166849ENOVVITR6885313005953010876881986887583006336699STAAINSP300298.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sinocare is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300049ELNCNMD6880166849ENOVVITR3005953010876881986699STAAINSP300298.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sinocare is the large dot.

Sinocare competitors and peer comparison

Head to head with its named competitors (300298.SZ vs 002432.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sinocare 300298.SZ$1.45B+4%+7%6%21.5×9.5%
Andon Health 002432.SZ$3.86B-24%-30%-26%16.1×-6.6%

How Sinocare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sinocare against its 20 peers (data as of 18 Nov 2026)
Measure300298.SZPeer medianRank in peer set
1-month return+5.6%-1.6%6th highest of 21
6-month return+4.0%-8.9%7th highest of 21
Distance from 52-week high-13.8%-30.3%3rd highest of 21
Revenue growth (TTM)+7.3%+12.1%9th lowest of 21
Operating margin5.7%8.2%9th lowest of 21
Forward P/E21.5×27.0×7th cheapest of 18
Growth the price implies (Req g, 7 yrs)9.5%18.4%5th least demanding of 15
Growth delivered (Del g)+18.3%+15.6%7th highest of 15
Hurdle (Req g minus delivered)-8.8 pp-3.8 pp5th least demanding of 15
ROIC minus cost of capital+2.2 pp-1.1 pp9th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%

Questions

Who are Sinocare's main competitors?
Named competitors: Andon Health (002432.SZ), Roche Diabetes Care (private or unlisted), Ascensia Diabetes Care (private or unlisted). The cockpit's measured peer set (industry) also includes Inner Mongolia Furui Medical Science (300049.SZ), PROCEPT BioRobotics (PRCT), El.En (ELN.MI), CONMED (CNMD), Shanghai MicroPort Endovascular MedTech (688016.SS), Nihon Kohden (6849.T).
Is Sinocare expensive compared with its peers?
On forward p/e it trades at 21.5× against a peer median of 27.0×, 7th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Sinocare stock performed?
Over six months to 18 Nov 2026 the shares returned +4.0% against -8.9% for the median peer; over one year -5.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.